Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
IKZF1 deletion + CDKN2B deletion
i
Other names:
IKZF1, IKAROS Family Zinc Finger 1, Zinc Finger Protein Subfamily 1A 1 (Ikaros), Protein Phosphatase 1 Regulatory Subunit 92, Ikaros Family Zinc Finger Protein 1, Lymphoid Transcription Factor LyF-1, DNA-Binding Protein Ikaros, ZNFN1A1, IKAROS, LYF1, IK1, IKAROS Family Zinc Finger 1 (Ikaros), CLL-Associated Antigen KW-6, Hs.54452, PPP1R92, PRO0758, CVID13, LyF-1, CDKN2B, Cyclin Dependent Kinase Inhibitor 2B, Cyclin-Dependent Kinase Inhibitor 2B (P15, Inhibits CDK4), Cyclin-Dependent Kinase 4 Inh
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
10320
;
1030
Related biomarkers:
Expression
Mutation
CNA
Others
‹
IKZF1 deletion (5)
IKZF1 deletion + CDKN2A deletion (2)
CDKN2B deletion (2)
IKZF1 deletion + IKZF3 deletion (1)
IKZF1 deletion + PAX5 deletion (1)
IKZF1 deletion + VPREB1 deletion (1)
MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion (1)
IKZF1 deletion + CDKN2A deletion + CDKN2B deletion + PAX5 deletion (0)
IKZF1 deletion (5)
IKZF1 deletion + CDKN2A deletion (2)
CDKN2B deletion (2)
IKZF1 deletion + IKZF3 deletion (1)
IKZF1 deletion + PAX5 deletion (1)
IKZF1 deletion + VPREB1 deletion (1)
MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion (1)
IKZF1 deletion + CDKN2A deletion + CDKN2B deletion + PAX5 deletion (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
IKZF1 deletion + CDKN2B deletion
Acute Myelogenous Leukemia
IKZF1 deletion + CDKN2B deletion
Acute Myelogenous Leukemia
ponatinib
Resistant: C3 – Early Trials
ponatinib
Resistant
:
C3
ponatinib
Resistant: C3 – Early Trials
ponatinib
Resistant
:
C3
IKZF1 deletion + CDKN2B deletion
Acute Lymphocytic Leukemia
IKZF1 deletion + CDKN2B deletion
Acute Lymphocytic Leukemia
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
dasatinib + blinatumomab
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.